登录
Xanomeline-Trospium: A Novel Therapeutic for the Treatment of Schizophrenia [0.03%] Xanomeline-Trospium：一种新型的精神分裂症治疗药物
Olivia L Ramey,Armando Silva Almodóvar Olivia L Ramey
Objective: This review describes a novel combination muscarinic agonist and antagonist, xanomeline-trospium, which was recently approved by the Food and Drug Administration (FDA) for schizophrenia. Efficacy and safety evi...
Time to Target Anti-Xa Level in Obese Vs Nonobese Patients Using an Adjusted Body Weight Heparin Infusion Protocol for the Treatment of Venous Thromboembolism [0.03%] 使用调整体重的肝素输注方案治疗静脉血栓栓塞时肥胖与非肥胖患者达到抗Xa目标水平的时间研究
Mary K Eibye,Jacqueline N Poston,Amanda G Kennedy et al. Mary K Eibye et al.
Background: Unfractionated heparin (UFH) is a first-line option for the acute treatment of venous thromboembolism (VTE). Weight-based dosing protocols have demonstrated a decreased time to therapeutic anticoagulation, how...
Therapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease [0.03%] GLP-1受体激动剂在代谢相关脂肪性肝病治疗中的潜力
Klaudia Nowak,Krzysztof Łupina,Anna Romac et al. Klaudia Nowak et al.
Objective: To summarize the current knowledge on the therapeutic potential of GLP-1 receptor agonists in managing metabolic associated steatotic liver disease (MASLD). ...
The Albumin-Bilirubin-Fibrosis-4 Score for Predicting Teicoplanin-Induced Abnormal Liver Enzyme Levels in Patients Undergoing Therapeutic Drug Monitoring: A Multicentral Retrospective Cohort Study [0.03%] 白蛋白-胆红素-肝纤维化4评分在治疗药物监测下预测茶剂平净诱导的异常肝脏酶水平：一项多中心回顾队列研究
Hayahide Ooi,Yuki Asai,Yoshihiro Kondo et al. Hayahide Ooi et al.
Background: Although therapeutic drug monitoring (TDM) maintains serum teicoplanin (TEIC) concentration between 15 and 30 μg/mL, TEIC-induced liver injury may still occur. The albumin-bilirubin (ALBI)-fibrosis-4 (FIB-4) ...
Adonice P Khoury,Jason Powell Adonice P Khoury
Objective: To review the published data including the pharmacology, efficacy, and safety of seladelpar, a peroxisome proliferator-activated receptor delta (PPARδ) agonist leading to the Food and Drug Administration (FDA)...
A Comparison of Outcomes of Standard Weight-Based and Capped Doses of Albumin for Spontaneous Bacterial Peritonitis [0.03%] 标准体重依赖型与固定剂量人血白蛋白治疗自发性细菌性腹膜炎的比较研究
Lily Huang,Avery Marcotte,Taryn S Murray et al. Lily Huang et al.
Background: Albumin is recommended in the management of patients with spontaneous bacterial peritonitis (SBP) to reduce rates of renal injury and mortality. Current guideline recommendations suggest an intravenous albumin...
Nitrofurantoin Versus Comparators in the Treatment of Cystitis due to Extended-Spectrum β-Lactamase-Producing Enterobacterales: A Multicenter Cohort Study [0.03%] 治疗由于可产生超广谱β内酰胺酶的肠杆菌科引起的膀胱炎中呋喃妥因与其他药物的对比：多中心队列研究
Abrar K Thabit,Khalid Al Sulaiman,Lulwa Alfaraj et al. Abrar K Thabit et al.
Background: The increasing prevalence of extended-spectrum β-lactamase (ESBL)-producing bacteria has limited treatment options for cystitis. The recommendation of nitrofurantoin for treatment is based solely on in vitro ...
Impact of Hypoalbuminemia on Clinical Outcomes in Patients Receiving Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia [0.03%] 低白蛋白血症对接受复方新诺明治疗的耐甲氧西林金黄色葡萄球菌所致血流感染患者的临床结局的影响
Kaylee M Whitenack,Dan Ilges,Kevin L Epps et al. Kaylee M Whitenack et al.
Background: Cefazolin is a preferred treatment option for methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. Recent studies have suggested a potential impact on clinical outcomes in patients with hypoalbumin...
The Impact of Ketamine-Based Versus Non-Ketamine-Based ECT Anesthesia Regimens on the Severity of Patients' Depression and Occurrence of Adverse Events: A Systematic Review with Meta-Analysis [0.03%] 基于氯胺酮与非氯胺酮电抽搐治疗麻醉方案对患者抑郁严重程度及不良事件发生率影响的系统评价和 meta 分析
Dakota J Sicignano,Rohan Kantesaria,Matthew Mastropietro et al. Dakota J Sicignano et al.
Objective: To compare efficacy and safety outcomes for ketamine anesthesia + electroconvulsive therapy (ECT) versus nonketamine anesthesia + ECT in treatment-resistant depression (TRD) patients. ...
Q32.32024 Review The Annals of pharmacotherapy. 2025 Mar;59(3):250-261. DOI:10.1177/10600280241260754 2025